Modulation of both tumor & T cell apoptosis to enhance CAR-T immunotherapy

Immuno-Oncology Insights 2022; 3(9), 527–539

DOI: 10.18609/ioi.2022.053

Published: 19 December 2022
Innovator Insight
Marco Ruella

CAR-T cell immunotherapy is leading to outstanding clinical results, but only one-third of patients have long-term responses in mature lymphomas. Resistance to apoptosis in cancer cells is a key feature of CAR-T immunotherapy failure, and strategies to enhance tumor apoptosis during CAR-T therapy lead to better tumor control. This article will highlight the importance of apoptosis in both cancer cells and CAR-T cells in driving response to CAR-T immunotherapy, and describes potential strategies to overcome resistance.